Primary CYP Enzymes That Metabolize Psychiatric Medications

Understanding CYP Enzymes and Their Roles

• The American College of Medical Genetics recommends understanding that CYP2D6 and CYP2C19 are the two main liver enzymes that break down most psychiatric medications, with CYP1A2 and CYP3A4 playing important supporting roles depending on the specific medication 1, 2
• The National Institute of Health states that CYP enzymes can be thought of as specialized workers in the liver whose job is to break down medications so the body can eliminate them, with different medications requiring different workers (enzymes) to process them 1

CYP Enzyme-Specific Roles and Variations

• The Mayo Clinic suggests that CYP2D6 breaks down many common antidepressants, including fluoxetine, paroxetine, and venlafaxine, and about 5-8% of Caucasians are "poor metabolizers" of this enzyme, leading to higher drug levels and more side effects 1, 2, 3
• The American Psychiatric Association notes that approximately 1-7% of the population are "ultrarapid metabolizers" of CYP2D6, who break down drugs too quickly, potentially leading to treatment failure 2, 3
• The National Institute of Mental Health indicates that CYP2C19 works alongside CYP2D6 to metabolize SSRIs and is particularly important for the metabolism of certain antidepressants, with about 2-5% of Caucasians being poor metabolizers for this enzyme 1, 3, 4

Clinical Implications of CYP Enzyme Variations

• The American College of Clinical Pharmacology states that genetic variations create different metabolizer types, including poor, intermediate, normal/extensive, and ultrarapid metabolizers, which can affect drug levels and the risk of side effects 2, 3
• The World Health Organization recommends considering that most psychiatric medications are broken down by more than one enzyme, so even if one enzyme doesn't work well, alternative pathways can partially compensate 1, 4

Limitations and Considerations

• The EGAPP Working Group found insufficient evidence that genetic testing for CYP enzymes improves clinical outcomes for patients starting SSRI treatment for depression, highlighting the complexity of the relationship between genotype and actual clinical response 5, 6
• The National Institute of Health notes that multiple factors, including diet, other medications, and individual patient characteristics, significantly affect drug metabolism, making it essential to consider these factors in clinical decision-making 1, 4

Pharmacogenetic Considerations for Psychotropic Medications

Patient-Specific Medication Recommendations

• The American Psychiatric Association recommends considering CYP2D6 and CYP2C19 genotype before initiating psychotropic medications, especially in patients with prior adverse reactions or treatment failures 7, 8, 9
• For CYP2D6 poor metabolizers, the Mayo Clinic recommends avoiding or reducing the dose of fluoxetine, paroxetine, and venlafaxine by 50% with mandatory therapeutic drug monitoring (TDM) 8, 9
• The National Institute of Mental Health suggests that CYP2D6 ultrarapid metabolizers may require higher doses of fluoxetine, paroxetine, and venlafaxine, and alternative agents should be considered 7, 8, 9
• For CYP2C19 poor metabolizers, the Clinical Pharmacogenetics Implementation Consortium recommends reducing the dose of citalopram and escitalopram by 50% 7, 9
• The European Psychiatric Association suggests that CYP2C19 ultrarapid metabolizers may require higher doses or alternative agents, and close monitoring is necessary 9

Medication Selection and Dosing

• The American College of Clinical Pharmacology recommends selecting medications with more predictable pharmacokinetics, such as sertraline, mirtazapine, and bupropion, in patients with CYP2D6 or CYP2C19 polymorphisms 7, 9
• The National Institute of Mental Health suggests that strong CYP2D6 inhibitors, such as fluoxetine and paroxetine, should be avoided in patients with CYP2D6 polymorphisms 8

Therapeutic Drug Monitoring

• The Clinical Pharmacogenetics Implementation Consortium recommends mandatory TDM for all poor metabolizers and ultrarapid metabolizers on fluoxetine, paroxetine, venlafaxine, and tricyclic antidepressants 7, 8
• The American Association for Clinical Chemistry suggests that TDM should be performed at steady state, and target ranges should be used to guide dosing adjustments 7, 8

Evidence Quality and Limitations

• The EGAPP Working Group found insufficient evidence that CYP genetic testing improves clinical outcomes for depression treatment, but this does not negate safety benefits in preventing toxicity 10
• The National Institute of Mental Health suggests that CYP genetic testing can help prevent adverse effects and toxicity in poor metabolizers, with strong evidence supporting its use in this population 8, 9

Genetic Testing for Antidepressant Selection

Technical Performance and Clinical Utility

• The American College of Medical Genetics recommends that genetic testing for CYP450 enzyme polymorphisms, specifically CYP2D6 and CYP2C19 genes, demonstrates high accuracy for common genetic variants, with analytic sensitivity ranging from 94-100% and analytic specificity of 100% for all genes tested 11, 12, 13
• The EGAPP Working Group found insufficient evidence that CYP450 genetic testing improves clinical outcomes, such as response rates, quality of life, and adverse events, in adults starting SSRI treatment for nonpsychotic depression, with a strength of evidence rated as low 11, 12, 13, 14
• Studies of patients on steady-state SSRI doses showed mixed results linking genotype to actual drug levels, highlighting the complexity of antidepressant metabolism 11, 12, 13
• Only five studies evaluated genotype versus clinical response, with inconsistent findings, indicating a need for further research 12
• No evidence demonstrates that using test results to guide SSRI choice or dose actually improves patient outcomes, suggesting that genetic testing should not be used as a routine screening tool 14
• The presence of drug interactions, diet, concomitant medications, and individual patient characteristics can significantly influence drug metabolism independent of genotype, highlighting the importance of considering multiple factors when interpreting genetic test results 14

CYP450 Genetic Testing for SSRI Metabolism

Test Components and Performance

• The FDA-approved Roche AmpliChip® CYP450 Test delivers results as both a genotype and a predicted metabolizer status for CYP2D6 and CYP2C19 enzymes, with many laboratories also offering their own laboratory-developed tests that meet Clinical Laboratory Improvement Amendment standards 15
• The analytic validity of CYP450 genotyping is high for common polymorphisms, with analytic sensitivity ranging from 94-100% and analytic specificity of 100% for all genes tested 16

Metabolizer Categories and Clinical Implications

• Patients can be classified into four metabolizer phenotypes: Ultra-rapid Metabolizers (UM), Extensive Metabolizers (EM), Intermediate Metabolizers (IM), and Poor Metabolizers (PM), with each category having distinct implications for drug concentrations and response at usual doses 15
• The American College of Medical Genetics and Genomics recommends considering CYP450 genotyping in patients with prior adverse reactions to multiple psychotropic medications, although routine testing is not recommended 16

Guideline Recommendations

• The EGAPP Working Group found insufficient evidence to recommend routine CYP450 genetic testing before starting SSRI treatment for nonpsychotic depression, citing evidence gaps including mixed results linking genotype to SSRI blood levels and lack of data demonstrating improved patient outcomes with test-guided treatment 16, 15